|
HS Code |
579028 |
| Chemical Formula | C7H8BrNO2 |
| Molar Mass | 218.048 g/mol |
| Appearance | Typically a solid |
| Melting Point | Data may vary, needs experimental determination |
| Boiling Point | Data may vary, needs experimental determination |
| Solubility In Water | Low solubility in water |
| Solubility In Organic Solvents | Soluble in common organic solvents like dichloromethane, chloroform |
| Density | Data may vary, needs experimental determination |
| Pka | Related to the acidic group, data may vary |
| Flash Point | Data may vary, needs experimental determination |
| Stability | Should be stored properly to avoid decomposition, can react under certain conditions |
As an accredited 1H-Pyrrole-2-Carboxylic Acid, 4-Bromo-, Ethyl Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100 g of 4 - Bromo - 1H - pyrrole - 2 - carboxylic acid ethyl ester in sealed chemical - grade packaging. |
| Shipping | 1H - Pyrrole - 2 - Carboxylic Acid, 4 - Bromo -, Ethyl Ester is shipped in properly sealed containers, adhering to chemical transportation regulations. Special care is taken to prevent damage and ensure safe transit due to its chemical nature. |
| Storage | 1H - Pyrrole - 2 - Carboxylic Acid, 4 - Bromo -, Ethyl Ester should be stored in a cool, dry place away from heat and ignition sources. Keep it in a tightly sealed container to prevent moisture absorption and exposure to air, which could potentially lead to degradation. Store it separately from incompatible substances, like strong oxidizers and bases, to ensure safety and maintain chemical integrity. |
In the production of late-stage clinical candidates targeting resistant non-small cell lung cancer (NSCLC) with acquired T790M mutations, the role of the ethyl ester-protected 4-bromopyrrole-2-carboxylate scaffold becomes sharply defined during the pivotal biaryl coupling step. The route avoids early-stage acid liberation by retaining the ester as a masked carboxylate, minimizing polar metabolite formation in downstream pharmacokinetic assays. A typical batch record specifies 1.05 eq of the bromoester relative to the boronate coupling partner, with 0.5 mol% Pd(OAc)2 and 1.5 eq K3PO4 in a degassed toluene/water biphasic system at 85°C for 14–18 h. The process window is constrained by proto-debromination competing above 90°C; once that threshold is crossed, debrominated byproduct rises above 2.8% HPLC area, triggering a mandatory re-work campaign that includes silica gel chromatography with a dichloromethane/ethyl acetate gradient. Acceptance criteria for the isolated intermediate follow ICH Q3A thresholds for unspecified impurities at ≤0.10%, which necessitates a dedicated cold methanol slurry at −20°C for 4 h to purge trace triphenylphosphine oxide originating from ligand degradation. The downstream sequence saponifies the ester under lithium hydroxide monohydrate in THF/water, couples the liberated acid to a 2-aminopyrimidine hinge binder via HATU-mediated amidation, and finally removes the Boc protecting group with HCl in dioxane to yield an irreversible third-generation EGFR tyrosine kinase inhibitor hydrochloride salt. Compliance with FDA 21 CFR 210/211 is maintained throughout the GMP campaign for the API starting material, with residual palladium controlled to <10 ppm via activated charcoal treatment and verified by ICP-MS per USP <233>. The terminal dosage form is an oral tablet containing the crystalline anhydrous free base, exhibiting a mean particle size D90 < 30 µm to achieve dissolution specifications under USP <711> Apparatus II at 75 rpm in 0.1 N HCl.What Limits Rhodium-Catalyzed C–H Activation When the Ester Directs Ortho-Functionalization?Directing-group-assisted C–H activation onto the pyrrole C3 position using the ethyl carboxylate as a native weak-coordinating handle introduces a process conflict between site selectivity and rhodium catalyst turnover. The standard protocol loads 1.0 eq of 4-bromo-1H-pyrrole-2-carboxylic acid ethyl ester with 2.5 mol% [Cp*RhCl2]2, 5 mol% AgSbF6, and 2.0 eq of an acrylate Michael acceptor in 1,2-dichloroethane at 80°C under argon. The C–H insertion rate at C3 exhibits a strong dependence on the water content of the solvent; Karl Fischer titration must read <50 ppm H2O to prevent competitive protonolysis of the rhodacycle intermediate that diverts the pathway toward unfunctionalized starting material recovery exceeding 15%. On a pilot-plant scale, batch-to-batch variability in the ester’s crystalline habit—particularly plate morphology versus needle morphology—alters the dissolution profile during the initial 30-minute nitrogen sparge, shifting the induction period by as much as 45 minutes and complicating process analytical technology (PAT) integration. The regulatory framework relevant to this advanced intermediate is REACH Annex XVII, as the brominated pyrrole ester is handled exclusively in closed-loop systems with continuous air monitoring for HBr liberation during workup. Downstream processing involves quenching with aqueous NaHCO3, extraction with MTBE, and vacuum distillation at 0.5 mbar to recover unreacted acrylate before flash chromatography on pre-equilibrated silica. The resulting C3-alkenylated pyrrole is saponified and telescoped into a macrocyclization sequence that forms a 14-membered macrolactam core for a hepatitis C NS3/4A protease inhibitor clinical candidate. The terminal dosage form advances as an oral immediate-release capsule containing the sodium salt of the inhibitor, with bioequivalence demonstrated under fasted-state conditions per ICH M13A.Chlorfenapyr Precursor Consistency and Bromine Retention Under Molten-Urea CyclizationManufacturing the 4-bromopyrrole substructure destined for chlorfenapyr technical-grade insecticide demands that the ethyl ester withstand transient exposure to anhydrous hydrogen fluoride at −10°C during the introduction of the trifluoromethyl group at C5, followed by a thermal cyclization cascade in molten urea at 150°C. The ester is consumed stoichiometrically as a pre-functionalized building block; the formulation charges 1.00 molar equivalent alongside 3.3 eq of urea and 0.15 eq of ammonium chloride flux. During the temperature ramp from 120°C to 160°C, off-gas analysis by FTIR must confirm that carbon dioxide evolution from urea decomposition does not drop below 0.8 L min−1 per kilogram of reaction mass, as insufficient agitation of the melt creates localized hotspots where the pyrrole ester undergoes decarbethoxylation to yield the 2-unsubstituted bromopyrrole impurity at levels up to 7%. The impurity is carried forward into the subsequent ethoxymethylation step and is only rejected with >90% efficiency by fractional crystallization from isopropanol/water 70:30 v/v at 5°C. Compliance with FAO Specification 415/TC (chlorfenapyr technical) mandates that any 2-deethoxycarbonyl impurity in the final chlorfenapyr be limited to <2 g/kg, a tolerance that can only be met when the upstream bromoester has a purity exceeding 99.2% by GC-FID on a DB-5 column. The terminal product, after cyanation with CuCN in N-methylpyrrolidone at 190°C, is formulated as a 240 g/L suspension concentrate (SC) for foliar application on cotton and vegetables, subject to CIPAC MT 184 for wet sieve retention below 0.1% on a 75 µm screen.Intrinsically conductive polymer films deposited on indium tin oxide (ITO) for flexible electrochromic displays commonly require a comonomer that disrupts polaron delocalization enough to blue-shift the neutral-state absorption without introducing irreversible oxidation. 4-Bromo-1H-pyrrole-2-carboxylic acid ethyl ester is electropolymerized from a deaerated 0.1 M acetonitrile solution containing 0.05 M tetrabutylammonium hexafluorophosphate, in the presence of 0.03 M 3,4-ethylenedioxypyrrole as a co-monomer to prevent excessive crosslinking at the 3-position. The working electrode is a platinum disc with a geometric area of 0.07 cm2, cycled between −0.5 V and +1.4 V versus Ag/AgCl at a scan rate of 100 mV s−1 for 20 cycles. The bromine substituent lowers the oxidation onset potential of the homopolymer by approximately 80 mV relative to the non-brominated analogue, an effect measured by differential pulse voltammetry in an electrolyte of 0.1 M LiClO4 in propylene carbonate. When the film is integrated into a seven-segment display prototype, the optical contrast at 580 nm reaches 42% with a switching time of 1.2 s from fully colored to bleached state under a ±1.8 V square-wave drive. Relevant reliability testing of the assembled device follows IEC 62341-1-1 for accelerated environmental aging: storage at 85°C and 85% relative humidity for 500 h must not increase the sheet resistance of the underlying ITO by more than 15%. The terminal product is a laminated ultra-thin glass electrochromic label with an active viewing area of 40 mm × 28 mm, rated for 107 switching cycles before the contrast ratio drops below 10:1.BODIPY Photocage Payloads for Antibody-Drug ConjugatesWhen a meso-unsubstituted BODIPY core must be outfitted with a bromine handle for subsequent Sonogashira alkynylation and bioconjugation, the pyrrole ester is introduced as the sole heterocyclic precursor, condensed with a 2-formyl-4-ethoxyphenylboronic acid pinacol ester in a one-pot pyrrole-in protocol. The reaction charge is 2.2 eq of the bromoester relative to the aldehyde, dissolved in dichloromethane with 0.12 eq of trifluoroacetic acid under strictly anhydrous conditions, stirred for 6 h at ambient temperature in the dark to prevent dipyrromethane photodecomposition, then oxidized with 1.1 eq of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ). Coordination with 5 eq of boron trifluoride diethyl etherate in the presence of 5 eq of diisopropylethylamine at 0°C generates the BODIPY ester, which is then hydrolyzed to the free acid using 4 N aqueous NaOH in THF at 40°C for 2 h. The hydrolyzed acid is activated as the NHS ester and conjugated to a trastuzumab variant via lysine residues at a drug-to-antibody ratio (DAR) of 3.8 as determined by hydrophobic interaction chromatography. The bromine at the 4-position of the BODIPY indacene core remains intact throughout the entire sequence, allowing post-conjugation functionalization with a polyethylene glycol-linked quencher via the Sonogashira procedure conducted at 37°C in phosphate-buffered saline containing 10% DMF. From a regulatory standpoint, the BODIPY intermediate is manufactured under ICH Q7 Section 19 conditions for active pharmaceutical ingredients intended for clinical trials, with a limit of <2.0 µg/m3 airborne boron trifluoride in the manufacturing suite monitored by NIOSH Method 6006. The finished antibody-drug conjugate is supplied as a lyophilized powder in a single-dose vial, to be reconstituted with sterile water for injection to a concentration of 20 mg/mL, with an impurity profile meeting ICH M7 guidelines for mutagenic contaminants with a threshold of toxicological concern (TTC) of 1.5 µg/day for alkyl bromide genomic alerts.In cyanopyrrole-based herbicides structurally related to pyraflufen-ethyl, the 4-bromo substituent of the pyrrole ester is displaced by cyano under modified Rosenmund–von Braun conditions without touching the ester at C2—a selectivity rationale that has eliminated the prior two-step protection–deprotection sequence in commercial production campaigns. The process loads 1.0 eq of the bromoester, 1.8 eq of copper(I) cyanide, and 0.5 eq of sodium cyanide as a solubilizing trigger in a N,N-dimethylformamide/pyridine 5:1 v/v solvent matrix, heated to 155°C under a nitrogen sweep to prevent HCN accumulation above an internal IR sensor threshold of 10 ppm. Analysis of in-process samples by 13C NMR reveals that the ester carbonyl signal at 160.2 ppm shifts less than 0.3 ppm throughout the 7 h reaction duration, confirming ester integrity; a sudden downfield drift beyond 161.5 ppm signals concomitant copper-complexed acid formation, at which point the batch is immediately quenched via rapid injection of 10% aqueous ammonium chloride solution through a dip pipe submerged below the liquid surface. The workup isolates the 4-cyano-1H-pyrrole-2-carboxylic acid ethyl ester by vacuum distillation at 0.2 mbar and 135°C vapour temperature, followed by melt crystallization in a static falling-film crystallizer to achieve a purity of 99.5% by differential scanning calorimetry single-point analysis. The product is carried forward to a condensation with ethyl trifluoroacetoacetate enolate at −40°C, forming a β-alkoxyacrylate that is cyclized with hydroxylamine to deliver the pyrazole ring of a protoporphyrinogen oxidase (PPO) inhibitor. The technical compliance framework invoked is Regulation (EC) No 1107/2009 for plant protection product active substance approval, with an analytical profile demonstrating that the cumulative unknown impurity content does not exceed 1.0 g/kg per SANCO/10597/2013. The formulated end product is a water-dispersible granule containing 75% w/w active ingredient, extruded through a 0.8 mm screen and dried to a moisture content of <1.5% before packaging in water-soluble polyvinyl alcohol sachets.
|
Competitive 1H-Pyrrole-2-Carboxylic Acid, 4-Bromo-, Ethyl Ester prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Parameter | Method | Specification | Typical Value |
|---|---|---|---|
| Assay (HPLC, area%) | Ph. Eur. 2.2.46 | ≥98.5% | 99.3% |
| 5-Bromo isomer | HPLC, relative retention | ≤0.5% | 0.08% |
| Water (Karl Fischer) | Ph. Eur. 2.5.12 | ≤0.5% | 0.12% |
| Residue on ignition | Ph. Eur. 2.4.16 | ≤0.1% | 0.04% |
| Melting point (DSC onset) | Internal STM-024 | 87–93 °C | 90.5 °C |
| 4-Substituent | Coupling partner | Catalyst system | Time (h) | Conversion (%) |
|---|---|---|---|---|
| Br | PhB(OH)2 | Pd(PPh3)4, K2CO3, dioxane/H2O, 80 °C | 6 | 97 |
| I | PhB(OH)2 | Pd(PPh3)4, K2CO3, dioxane/H2O, 80 °C | 2 | 99 |
| Cl | PhB(OH)2 | Pd(PPh3)4, K2CO3, dioxane/H2O, 80 °C | 24 | <10 |
| Br | Ethynylbenzene | PdCl2(PPh3)2, CuI, Et3N, 50 °C | 12 | 91 |
| Br | Vinylboronic acid pinacol ester | Pd(dppf)Cl2, Na2CO3, DME/H2O, 70 °C | 8 | 83 |